In paediatric patients with a body surface area >1.2 m2 requiring MCS, the use of an implantable CF-LVAD is feasible because results are non-inferior to those with extracorporeal devices [275, 289, 290], and discharge from the hospital is possible, resulting in a better quality of life [275, 277, 284, 285, 290]. In adults, CF-VADs have improved survival and greater freedom from stroke and device failure compared with pulsatile devices [147]. This result seems to be true also for paediatric patients with a body surface area >1.2 m2 and without CHD [275, 277, 279, 290].